Despite efforts to curb overdiagnosis of thyroid cancer, the issue has continued to plague U.S. healthcare, according to ...

used in combination with ThyGeNEXT ®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX ®, that ...

Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences ...

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

A large-scale study of low-risk thyroid cancer patients proved that the quality of life can be maintained with 'active ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Many people frequently ask me why cancer seems more prevalent today than in the past or why cancer patients often succumb to the disease more quickly than those with other conditions. One of the most ...

The immediate threat has passed, at least for now. But concern from individuals, businesses, nonprofits and local governments ...

Chicago Partners Investment Group LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the ...

Genmab A/S (NASDAQ:GMAB – Get Free Report) is projected to announce its earnings results on Wednesday, February 12th. Analysts expect the company to announce earnings of $0.28 per share and revenue of ...

An Iranian knowledge-based company has managed to develop a new method for the synthesis of Technetium (99mTc) tilmanocept, a radiopharmaceutical diagnostic imaging agent used to determine lymph nodes ...